Background: HAART can cause mitochondrial DNA (mtDNA) depletion, which may lead to mitochondrial dysfunction. We aimed to determine whether mtDNA and mitochondrial function abnormalities are present in peripheral blood mononuclear cells from asymptomatic HIV-infected children. Methods: A cross-sectional study in peripheral blood mononuclear cells was performed in 47 asymptomatic (free from any HIV-or AIDS-related active condition or HAART-related toxicity), HIV-infected, HAART-treated children and adolescents and 27 uninfected healthy paediatric patients. We measured mtDNA and mitochondrial RNA (mtRNA) content by quantitative real-time PCR. Mitochondrial respiratory chain enzymatic activity of complex-IV (CIV) and mitochondrial mass (estimated by citrate synthase) were measured spectrophotometrically, and CIV protein subunit content was measured with western blot analysis.
HAART has improved morbidity and mortality from HIV infection and AIDS, including among paediatric patients [1] . HAART-related toxicities are increasingly being reported in HIV-infected children as well [2, 3] . In children, HAART generally includes two or more nucleoside reverse transcriptase inhibitors (NRTIs), which inhibit both HIV transcriptase and DNA polymerase-γ [4] [5] [6] . As DNA polymerase-γ is the only enzyme responsible for mitochondrial DNA (mtDNA) replication and mtDNA repair, the presence of mtDNA depletions, multiple deletions and point mutations has been described in HIVinfected patients receiving NRTIs [4, 5] . Since mtDNA codifies for 13 proteins of the oxidative phosphorylation system responsible for cellular respiration and aerobic energy production, a reduced content of protein subunits in some complexes of the mitochondrial respiratory chain (MRC) and abnormalities in MRC activities have also been observed in adults [7] . Our understanding of the complexity of HAART-related mitochondrial toxicity has increased with the recent description of compensatory homeostatic mechanisms [8] and alternative pathogenic pathways different from DNA polymerase-γ inhibition [9] [10] [11] . Furthermore, protease inhibitors (PIs) [12] and non-nucleoside reverse transcriptase inhibitors (NNRTIs) [13] have been associated with some effects on mitochondrial-dependent apoptotic pathways.
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Introduction
Mitochondrial toxicities have been scarcely studied in the paediatric population. HAART-associated mitochondrial toxicity in children has varied clinical presentations, comparable to those affecting the HIV-infected adult, but also comparable to children with congenital mitochondrial diseases. The fact that children will be exposed to antiretrovirals (ARVs) for an ever-increasing length of time throughout postnatal growth and development should not be forgotten. A few studies, with small numbers of patients and no healthy controls, have quantified mtDNA content in HAART-treated HIV-infected children, and they have failed to demonstrate depletion [14, 15] , without yielding further insight into the pathogenesis underlying these findings. In this study, we aim to reveal whether there is HAART-related depletion of mitochondrial genome in a large series of asymptomatic, HIV-infected, HAART-treated, paediatric patients and, if it is present, to determine whether it is reflected at the transcriptional, translational or functional levels.
Methods
A cross-sectional study was conducted in a series of consecutive asymptomatic HIV-infected HAARTtreated children and adolescents (n=47) belonging to a larger cohort of HIV-infected paediatric patients followed-up in a tertiary-care paediatric centre in Barcelona, Spain. At inclusion, being free from any HIVor AIDS-related clinical condition and HAART-related toxicity was required; the latter included any clinical sign or symptom consistent with hyperlactataemia, myopathy, neuropathy or fat redistribution, which were assessed by means of clinical interview, patients and parents self-report, and physical exam. A sex-and age-matched control group of HIV-uninfected healthy paediatric patients referred for presurgical routine analysis was used (n=27). Local ethics committee approval and informed consent from parents or legal guardians were obtained at inclusion.
Peripheral blood mononuclear cells (PBMCs; lymphocytes and monocytes) were obtained from 5-10 ml of venous blood. PBMCs were isolated by centrifugation, using a Ficoll's gradient (Histopaque 1077; Sigma Diagnostics, St Louis, MO, USA) [16] . Less than 200 platelets were counted for each PBMC. Isolated PBMCs were cryopreserved at -80°C. Total protein content of cells was measured using Bradford's reagent method at 595 nm [17] . Mitochondrial mass (MM) was estimated by citrate synthase (CS) activity, using an enzyme located in the mitochondrial matrix that acts in Krebs cycle [18, 19] , and by western blot analysis, assessed as the ratio between the mitochondrial voltage-dependent anion channel (VDAC) and the cytoplasmatic β-actin protein [8] .
As a representative of replication efficiency, we quantified mtDNA content by quantitative real-time PCR (LightCycler FastStart DNA Master SYBR Green I; Roche Molecular Biochemicals ® , Mannheim, Germany), separately analysing a fragment of the highly conserved ND2 mitochondrial-encoded (mtND2) gene and a sequence of the housekeeping nuclear-encoded 18SrRNA gene (n18S). Extensive methodology is reported elsewhere [7] . The results were expressed as the ratio between mtND2 gene and n18S gene [20] .
As a representative of transcriptional efficiency, mitochondrial RNA (mtRNA) was extracted by means of an affinity column-based procedure (RNA II, Nucleospin ® ; Cultek, Madrid, Spain) and reversely transcribed (GeneAmp PCR System 2400; Perkin Elmer, Rodgau, Germany) using random primers (TaqMan reverse transcriptase; Applied Biosystems, Foster City, CA, USA) in a total reaction volume of 20 µl. For each extract, mtRNA was assessed by quantitative real-time PCR (LightCycler FastStart DNA Master SYBR Green I). Quantification of ND2 mtRNA was performed using the forward 5′-GCCCTAGAAATAAACATGCTA-3′ and the reverse 5′-GGGCTATTCCTAGTTTTATT-3′ sequences. The results were expressed as the ratio between mtND2 RNA and n18S RNA.
As a representative of translational efficiency, cytochrome c oxydase (CIV or COX) subunits II (COXII; mitochondrial-encoded) and IV (COXIV; nuclearencoded) were quantified by western blot analysis, and expressed as the ratio of COXII/COXIV [8] .
As a representative of functional efficiency, MRC enzymatic activity was evaluated using the methodology of Rustin et al. [21] , slightly modified for mitochondrial CIV measurement in minute amounts of biological sample [22] . Enzymatic activities were expressed as absolute values in nmol/min/mg. All absolute measurements were corrected by MM in order to exclude any influence of mitochondrial proliferation or reduction in such values. This correction was performed by dividing mtDNA content, mtRNA content and CIV activity by CS activity, and COXII/COXIV ratio by VDAC.
Statistical analysis
Mitochondrial assessment results were expressed as mean ±sem, and those of HIV-infected children were expressed as percentages of control values, which were arbitrarily assigned to 100%. The KolmogorovSmirnov test was performed to ascertain the normal distribution of data. Groups with normal data were compared using the Student's t-test on unrelated samples. Non-normally distributed parameters were analysed with the non-parametric Mann-Whitney U test. Linear regression analysis was used to uncover any relationship between quantitative variables. Statistical significance was considered when a P-value was <0.05.
Statistical analysis was performed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics of the 47 asymptomatic HIVinfected HAART-treated children included in the study are summarized in Table 1 . At the time of assessment, none of the patients in our study showed clinically significant signs or symptoms consistent with HAARTrelated toxicities or other active conditions. MM, estimated by means of CS activity and VDAC content (Figure 1 ), remained similar in HIV-infected children and healthy controls (n=27, 52% females, 89% Caucasian race, median age 12.3 years).
The mtDNA content was 23% lower in HIV-infected HAART-treated children with respect to healthy controls (mean mtND2/n18s gene ratios ±sem 4.47 ±0.31 versus 5.82 ±0.48; P=0.018); conversely, mtRNA, mitochondrial protein content and CIV activity were not significantly different between groups (Figure 2 ). When all these parameters were corrected by MM, nearly identical results were found ( Figure 3 ): mtDNA depletion with indemnity of all other mitochondrial downstream parameters.
Regarding the mtDNA depletion found among HIVinfected HAART-treated children, mtDNA amount was not associated with gender, age or lactate levels (normal range 0.55-1.77 mmol/l), CD4 + T-cell counts, and HIV plasmatic viral load at the time of assessment. Receiving an ARV combination containing didanosine, zidovudine or stavudine, or being allocated on a PI-based regimen (lopinavir/ritonavir n=10 or fosamprenavir/ritonavir n=8) did not influence the degree of mtDNA depletion. Finally, no differences were observed in mitochondrial parameters when current therapeutic regimens were taken into account (time period on HAART regimen, individual use of each of the NRTIs and tenofovir, and use of the following combinations: zidovudine plus lamivudine/emtricitabine, abacavir plus lamivudine/emtricitabine and tenofovir plus lamivudine/emtricitabine; CM et al., data not shown).
After excluding those patients not vertically infected (n=3), 27 out of 44 children (61%) had been treated with suboptimal NRTI monotherapy or bitherapy before HAART implementation. These patients were younger at HIV infection diagnosis (mean values 0.78 versus 3.05 years; P=0.028), had been on ARV (13.01 versus 6.21 years; P=0.006) and on HAART (9.09 versus 6.21 years; P<0.001) treatment longer, and had developed AIDS more often (52% versus 15%; P=0.009) than children who were initially treated with a HAART regimen. Again, no differences in mtDNA content or mitochondrial function parameters were observed between these two groups. Overall, median 
Discussion
To date, three studies have investigated mtDNA levels in the PBMCs of HIV-infected children. Saitoh et al. [23] , in a 104-week follow-up of 31 patients on stable HAART and suppression of viral replication, identified didanosine as the only NRTI associated with mtDNA suppression in PBMCs before and during HAART. Another study showed no difference in PBMC mitochondrial function or mtDNA content between HIV-infected children with (n=6) or without (n=12) lipodystrophy [14] . Recently, mtDNA evolution was investigated in a group of 18 HIV-infected children who were randomized either to continue on a stavudine-containing HAART regimen (arm A, n=9) or to switch to tenofovir (Arm B, n=9); no changes were noted in PBMC mtDNA levels after 18 months of follow-up [15] . To our knowledge, our study is the first one to investigate not only mtDNA content, but also mtRNA, mitochondrial protein subunits content and mitochondrial function in a large series of asymptomatic, HIV-infected, HAARTtreated patients in the paediatric age. As opposed to previous reports, which describe relevant variability in the mtDNA content and which do not show any mtDNA depletion in HIV-infected children [14, 15] , we found a 23% decrease in mtDNA in PBMCs of asymptomatic, HIV-infected, HAART-treated children when compared with HIV-negative healthy controls. This difference may be due to the greater number of patients recruited in this study. Mitochondrial DNA depletion was not reflected in a decrease of mtRNA amount or in the content of protein subunits, nor, consequently, in function. Therefore, although statistically significant, mtDNA depletion appears to have no current clinical or cellular consequences in the patients we present. Whether these alterations in mtDNA content will become clinically significant in the presence of precipitating factors or persist into adulthood remains unknown.
The fact that mtDNA depletion was not associated with unaltered transcriptional, translational and functional efficiency may be explained by different hypothesis. It is possible that changes in mtDNA and mitochondrial function in PBMCs are not good markers of mitochondrial toxicity in organ-specific tissue, especially in those tissues more dependent on oxidative phosphorylation, such as muscle [24] . By contrast, we previously hypothesized that, in HIV-infected adults, up-regulatory transcriptional or post-transcriptional mechanisms could compensate for mtDNA depletion as well [8] . Supporting the latter view, the differences in mtDNA were not reflected in mtRNA content in our study. Furthermore, since we only observed mild mtDNA depletion (23%), another explanation for the normal mtRNA amount, protein subunit content and function is that only mtDNA defects involving >80% of the genetic material are able to induce MRC failure and cellular dysfunction, potentially leading to clinically significant symptoms [25] . Compensatory mechanisms, especially an increase in the transcriptional rate, are probably sufficient to maintain mitochondrial function.
Several studies in adults have described decreased mtDNA levels in HIV-infected ARV-naive patients, confirming the role that HIV infection by itself plays in mitochondrial dysfunction. Saitoh et al. [23] , in a longitudinal study of 31 children, showed a negative correlation between mtDNA and intracellular HIV DNA levels in PBMCs in early stages of HAART, and afterwards they found that didanosine-containing HAART regimens led to smaller increases in mtDNA over time when compared with other regimens, demonstrating that the beneficial effect of decreasing viraemia in mtDNA replication may be masked by the negative effect of some NRTIs on mitochondria. By contrast, not only the use of NRTIs, but also exposure to PIs and NNRTIs has been recently associated with mitochondrial damage [12, 13] . In our study, current or past use of ARV families and drugs, clinical characteristics, and immunological or virological parameters were not associated with differences in mtDNA content. The cross-sectional study that we present does not allow us to draw causal conclusions, but both long-term exposure to HAART and complete viral suppression at the time of assessment in most patients suggest that the depletion in mtDNA that we observed is attributable to the long-term use of ARV rather than to a harmful effect of HIV. Accordingly, we recently reported that planned interruption of HAART led to a partial restoration of mtDNA levels and a significant decrease in lactate values in a series of 13 asymptomatic vertically HIV-infected children [26] . The small sample size and the heterogeneity in the characteristics of the patients studied are major limitations of our study and hampered identification of the risk factors of mitochondrial damage that several authors have previously described. As an example, only eight and two children, respectively, were receiving stavudine or didanosine, the most harmful NRTIs, at the time of assessment, but 34 out of 47 of the patients had previously received one or the other of those drugs for a mean cumulative time of 91 months. Finally, excluding those patients with symptomatic HAART-related toxicities probably represents a selection bias in our study that may depict the mildest form of the toxicity spectrum, since some of these adverse effects have been associated with mitochondrial dysfunction in HIV-infected adult patients [7, 11, 24] .
In summary, we detected mtDNA depletion in PBMCs from asymptomatic HIV-infected children receiving HAART. This depletion was not reflected in differences in mtRNA or in structural or functional enzymatic activities of MRC. These results are consistent with the large body of evidence available on the pathogenesis of HIV-related and ARV-related mitochondrial toxicity in the HIV-infected adult patient. In the investigation of mitochondrial toxicity, PBMCs remain, despite their well-known limitations, the tissue of choice with regard to ease of sampling and analysis, especially among children. Further investigation is needed to better define mitochondrial toxicity pathways in HIV-infected paediatric patients who develop adverse effects, but also to determine the long-term clinical significance of these findings in asymptomatic children.
